Dr. Andrew Hong, MD

• Pediatric Hematology & Oncology

• Pediatrics

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Boston Children's Hospital/dana-farber Cancer Institute, Pediatric Hematology/oncology

  Fellowship Hospital, 2014

• Boston Combined Residency Program, Pediatrics

  Residency Hospital, 2011

• University Of Chicago Pritzker School Of Medicine

  Medical School, 2009

• Boston Combined Residency In Pediatrics

  Internship Hospital, 2009

• MDM2 and MDM4 are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors, 2019-02-12

• Emerging Opportunities for Target Discovery in Rare Cancers, 2017-09-21

• Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma, 2018-09-12

• MCL1 and DEDD promote urothelial carcinoma progression, 2019-02-18

• Renal medullary carcinomas depend uponSMARCB1loss and are sensitive to proteasome inhibition, 2019-03-12

• CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer, 2019-11-19

• A First-Generation Pediatric Cancer Dependency Map, 2021-03-22

• Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine, 2020-07-06

• Deubiquitinases maintain protein homeostasis and survival of cancer cells upon glutathione depletion, 2019-02-21

• Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q, 2020-12-15

• Integrated genetic and pharmacologic interrogation of rare cancers, 2016-06-22